Complex findings in diabetes

Amylin Pharmaceuticals Inc. late Friday announced positive results from the first two of six Phase III trials of its pramlintide synthetic analog of the hormone amylin in patients with Type I and Type II diabetes. However, it may take investors awhile to digest the complex results.

Data were statistically significant in the subgroup of patients that match the enrollment and treatment criteria of the company's four ongoing Phase III trials, which are intended for registration of the product.